Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Bluebird Bio
Bluebird Bio
Bluebird’s Zynteglo safety snag could spell trouble for other gene therapies: analysts
Fierce Pharma
Thu, 02/18/21 - 09:52 pm
gene therapy
Bluebird Bio
Zynteglo
clinical trials
Bluebird stops studies of sickle cell gene therapy after new cancer cases
BioPharma Dive
Tue, 02/16/21 - 11:19 am
Bluebird Bio
gene therapy
sickle cell disease
leukemia
clinical trials
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
JPM: Bluebird to spin off cancer therapies into new company
Fierce Biotech
Mon, 01/11/21 - 10:26 am
Bluebird Bio
spinoffs
oncology
JPMHC 2021
Oncology Newco
10 Biopharma Stories to Look Forward to in 2021
BioSpace
Sun, 01/3/21 - 04:39 pm
pandemic
COVID-19
vaccines
Joe Biden
drug pricing
M&A
venture capital
JNJ
Biomarin
Bluebird Bio
TG Therapeutics
Biogen
AstraZeneca
3 FDA Dates Biotech Investors Should Circle in 2021
Motley Fool
Sat, 12/26/20 - 08:27 pm
FDA
biotech
Bluebird Bio
ide-cel
Multiple Myeloma
Biogen
aducanumab
Alzheimer's disease
targeted therapeutics
umbralisib
maringal zone lymphoma
Bluebird trumpets long-term data from beta-thalassaemia gene therapy
Pharmaforum
Wed, 12/9/20 - 10:40 am
Bluebird Bio
Zinteglo
gene therapy
beta-thalassemia
FDA gene therapy holdups suggest closer scrutiny by agency
BioPharma Dive
Fri, 11/6/20 - 10:07 am
FDA
gene therapy
Sarepta Therapeutics
Voyager Therapeutics
Iovance
Bluebird Bio
Can bluebird bio Recover From Another Major Setback?
Motley Fool
Fri, 11/6/20 - 10:00 am
Bluebird Bio
bb1111
sickle cell disease
FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay
Endpoints
Thu, 11/5/20 - 11:05 am
Bluebird Bio
FDA
sickle cell disease
gene therapy
HGB-206
FDA grants priority review to ide-cel, keeping Bristol Myers on track to deliver Celgene payday
Fierce Biotech
Tue, 09/22/20 - 12:18 pm
Bristol-Myers Squibb
Celgene
Bluebird Bio
FDA
priority review
ide-cel
Bristol Myers resubmits cancer cell therapy, lifting investors' chance at payout
BioPharma Dive
Thu, 07/30/20 - 12:01 am
Bristol-Myers Squibb
Bluebird Bio
FDA
ide-cel
cell therapy
Multiple Myeloma
New CRISPR, gene therapy results strengthen potential for treatment of blood diseases
BioPharma Dive
Fri, 06/12/20 - 11:11 am
CRISPR
gene therapy
beta thalassemia
sickle cell disease
CRISPR Therapeutics
Vertex
Bluebird Bio
EHA
EHA 2020 – Bluebird’s sickle cell plan takes shape, with a stark reminder
EP Vantage
Fri, 06/12/20 - 10:41 am
Bluebird Bio
sickle cell disease
LentiGlobin
EHA
What Sanofi Might Buy With Its Regeneron Windfall
Barron's
Wed, 05/27/20 - 11:01 am
Sanofi
Regeneron
M&A
gene therapy
Ultragenyx
Bluebird Bio
FDA Mishaps Have Investors Asking “What’s Going On With bluebird bio?”
Motley Fool
Sun, 05/24/20 - 10:19 pm
Bluebird Bio
beta thalassemia
LentiGlobin
FDA
pandemic
clinical trials
Biotech companies raise cash as coronavirus updates lift stocks
BioPharma Dive
Tue, 05/19/20 - 11:24 pm
biotech
biotech stocks
COVID-19
Moderna Therapeutics
Bluebird Bio
Turning Point Therapeutics
Gossamer Bio
Krystal Biotech
Clovis Oncology
Gamida Cell
Bellerophon
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Thu, 05/14/20 - 10:56 pm
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Bristol Myers Squibb Receives a 'Refuse to File' Letter for an Experimental Cancer Therapy on a Deadline
Motley Fool
Wed, 05/13/20 - 11:21 am
Bristol-Myers Squibb
Bluebird Bio
refusal to file letter
FDA
ide-cel
Bristol Myers Squibb Offers bluebird bio a $200 Million Royalty Buyout
Motley Fool
Mon, 05/11/20 - 11:36 pm
Bristol-Myers Squibb
Celgene
M&A
Bluebird Bio
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »